Ecstasy cannot be assumed to be 3,4-methylenedioxyamphetamine (MDMA)

British Journal of Pharmacology

Volumn 166, Issue 5, 2012, Pages 1521-1522

  Green, A R ^a   King, M V ^a   Shortall, S E ^a   Fone, K C F ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN;

BODY TEMPERATURE; DRUG DEPENDENCE; DRUG MISUSE; EXPOSURE; HAIR ANALYSIS; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERTHERMIA; MENTAL DISEASE; NEUROTOXICITY; NONHUMAN; NOTE; PLASMA HALF LIFE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; SEROTONIN METABOLISM; SPECIES DIFFERENCE; TOXICOKINETICS; URINALYSIS;

EID: 84862750371     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01940.x     Document Type: Note

References (14)

1. 2C receptor responsivity. Neuropharmacology 44: 439-448.
2. Camarasa J, Pubill D, Escubedo E, (2006). Association of caffeine to MDMA does not increase antinociception but potentiates adverse effects of this recreational drug. Brain Res 1111: 72-82.
3. Docherty JR, Green AR, (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol 160: 1029-1044.
4. Fone KCF, Beckett SRG, Topham IA, Swettenham J, Ball M, Maddock L, (2002). Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159: 437-444.
5. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI, (2004). Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 173: 264-269.
6. Green AR, King MV, Shortall SE, Fone KCF, (2012). Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br J Pharmacol 166: 1523-1536.
7. Hamida SB, Tracqui A, de Vasconcelos AP, Szwarc E, Lazarus C, Kelche C, et al,. (2009). Ethanol increases the distribution of MDMA to the rat brain: possible implications in the ethanol-induced potentiation of the psychostimulant effects of MDMA. Int J Neuropsychopharmacol 12: 749-759.
8. O'Shea E, Granados R, Esteban B, Colado MI, Green AR, (1998). The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37: 919-926.
9. Parrott AC, Gibbs A, Scholey AB, King R, Owens K, Swann P, et al,. (2011). MDMA and methamphetamine: some paradoxical negative and positive mood changes in an acute dose laboratory study. Psychopharmacology 215: 527-536.
10. Parrott AC, (2012). MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans-no need for translation. Br J Pharmacol 166: 1518-1520.
11. Rodsiri R, Spicer C, Green AR, Marsden CA, Fone KCF, (2011). Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology 213: 365-376.
12. Vanattou-Saïfoudine N, McNamara R, Harkin A, (2010). Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats. Br J Pharmacol 160: 860-877.
13. Verheyden SL, Maidment R, Curran HV, (2003). Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 17: 371-378.
14. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ, (2009). Content of ecstasy in the Netherlands: 1993-2008. Addiction 104: 2057-2066.